$PMHS
Polomar Health Services, Inc.

2023 Q4 Form 10-Q Financial Statement

#000166357723000542 Filed on November 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $4.526K
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00 $4.526K
YoY Change
Gross Profit Margin 100.0%
Selling, General & Admin $18.41K $70.66K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $18.40K $70.66K $18.04K
YoY Change 291.58%
Operating Profit -$18.40K -$70.66K -$13.52K
YoY Change 422.69%
Interest Expense $0.00 -$50.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$37.49K $77.00
YoY Change -48781.82%
Pretax Income -$127.6K -$108.1K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$127.6K -$108.1K -$13.44K
YoY Change 704.57%
Net Earnings / Revenue -296.97%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 109.1M shares 108.6M shares 266.2K shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $240.00 $15.08K
YoY Change
Cash & Equivalents $224.00 $15.08K $4.604K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00
YoY Change
Inventory $3.459K
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00 $113.9K
Total Short-Term Assets $244.00 $129.0K
YoY Change -99.91%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $94.83K
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $244.00 $129.0K
Total Long-Term Assets $0.00 $0.00
Total Assets $244.00 $129.0K
YoY Change -99.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.78K $10.21K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $4.700K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.78K $14.91K
YoY Change -81.55%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.78K $14.91K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $13.78K $14.91K
YoY Change -81.55%
SHAREHOLDERS EQUITY
Retained Earnings -$1.398M -$1.271M
YoY Change 42.42%
Common Stock $109.1K $109.1K
YoY Change 1.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.54K $114.1K -$65.05K
YoY Change
Total Liabilities & Shareholders Equity $244.00 $129.0K
YoY Change -99.91%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$127.6K -$108.1K -$13.44K
YoY Change 704.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$10.14K -$117.3K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.700K 104.3K
YoY Change
NET CHANGE
Cash From Operating Activities -10.14K -117.3K
Cash From Investing Activities
Cash From Financing Activities -4.700K 104.3K
Net Change In Cash -14.84K -12.93K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$10.14K -$117.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
usd
us-gaap Cost Of Revenue
CostOfRevenue
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001265521
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
usd
CY2023Q3 us-gaap Revenues
Revenues
usd
us-gaap Revenues
Revenues
usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
usd
CY2022Q3 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
CY2023Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
usd
CY2022Q2 TRFE Return And Cancellation Of Common Stock During Period
ReturnAndCancellationOfCommonStockDuringPeriod
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Interest Paid
InterestPaid
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
usd
CY2023Q3 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
usd
CY2022Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56555
dei Entity Registrant Name
EntityRegistrantName
Trustfeed Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-1006313
dei Entity Address Address Line1
EntityAddressAddressLine1
140 Broadway
dei Entity Address Address Line2
EntityAddressAddressLine2
46th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10005
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
490-7454
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109138049 shares
CY2023Q3 us-gaap Cash
Cash
15084 usd
CY2022Q4 us-gaap Cash
Cash
225619 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
30000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5865 usd
CY2023Q3 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
113882 usd
CY2022Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
0 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
128966 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
261484 usd
CY2023Q3 us-gaap Assets
Assets
128966 usd
CY2022Q4 us-gaap Assets
Assets
261484 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
10212 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5012 usd
CY2023Q3 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
4699 usd
CY2022Q4 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
69703 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14911 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
74715 usd
CY2023Q3 us-gaap Liabilities
Liabilities
14911 usd
CY2022Q4 us-gaap Liabilities
Liabilities
74715 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
500000 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
500 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
109138 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
107582 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1275156 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1023476 usd
CY2022Q4 us-gaap Payable Common Stock Redeemed
PayableCommonStockRedeemed
37044 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1270739 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-981833 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
114055 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
186769 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128966 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261484 usd
CY2022Q3 us-gaap Revenues
Revenues
4526 usd
us-gaap Revenues
Revenues
4526 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
4526 usd
us-gaap Gross Profit
GrossProfit
4526 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
70657 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18044 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
251421 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34002 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
70657 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
18044 usd
us-gaap Operating Expenses
OperatingExpenses
251421 usd
us-gaap Operating Expenses
OperatingExpenses
34002 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-70657 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13518 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-251421 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-29476 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
77 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
77 usd
CY2023Q3 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37485 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
77 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-37485 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
77 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-108142 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13441 usd
us-gaap Profit Loss
ProfitLoss
-288906 usd
us-gaap Profit Loss
ProfitLoss
-29399 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
CY2022Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.00
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.10
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
108166142 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
266157 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
107726216 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
292430 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
186769 usd
CY2023Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
110192 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-89806 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
207155 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-90958 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
116197 usd
CY2023Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
106000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-108142 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
114055 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-35646 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2250 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-37896 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13708 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-51604 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13441 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-65045 usd
us-gaap Net Income Loss
NetIncomeLoss
-288906 usd
us-gaap Net Income Loss
NetIncomeLoss
-29399 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
20000 usd
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5865 usd
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
151314 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5200 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4078 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-361723 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25321 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
216192 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2564 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
29925 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
-67568 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151188 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29925 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-210535 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4604 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
225619 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15084 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4604 usd
TRFE Return And Cancellation Of Common Stock
ReturnAndCancellationOfCommonStock
95000 usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2000-09-14
us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_842_eus-gaap--BasisOfAccounting_zuhpnpRfV0y3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt"><i><span style="text-decoration: underline">Basis of presentation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify">The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify">The financial statements have been prepared in accordance with accounting principles generally accepted in The United States of America and the rules and regulations of the OTC Markets alternative reporting standard for interim financial information. Accordingly, they do not include all the information necessary for a comprehensive presentation of financial position and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify">It is management's opinion, however, that all material adjustments (consisting of normal and recurring adjustments) have been made which are necessary for a fair financial statements presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"> </p> <p style="font: 8.5pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"></p>
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_zZOEyTGaoSC1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt"><i><span style="text-decoration: underline">Use of estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5pt; text-align: justify"><i> </i></p>
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Cash
Cash
15084 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1270739 usd
us-gaap Net Income Loss
NetIncomeLoss
-288906 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-361723 usd
CY2023Q3 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
37432 usd
CY2023Q3 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
113882 usd
CY2022Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
0 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
295000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On June 3, 2022, the Board authorized the execution of a reverse split of the issued and outstanding shares of the Corporation’s common stock at a ratio of up to one post-split share per two thousand pre-split shares (1:2,000) at a time and exact ratio amount the Board of Directors deems appropriate. On September 2, 2022, FINRA approved a 1-for-2,000 reverse stock split of the Company’s common stock that was approved by the Company’s Board of Directors.
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109138049 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109138049 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
107582614 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
107582614 shares
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares

Files In Submission

Name View Source Status
0001663577-23-000542-index-headers.html Edgar Link pending
0001663577-23-000542-index.html Edgar Link pending
0001663577-23-000542.txt Edgar Link pending
0001663577-23-000542-xbrl.zip Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_002.gif Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
trfe-20230930.xsd Edgar Link pending
trfe10q093023.htm Edgar Link pending
trfe-20230930_def.xml Edgar Link unprocessable
trfe-20230930_cal.xml Edgar Link unprocessable
trfe-20230930_lab.xml Edgar Link unprocessable
trfe-20230930_pre.xml Edgar Link unprocessable
trfe10q093023_htm.xml Edgar Link completed